News Novartis' CAR-T drug needs new payment model, says Express S... Cost of Novartis' revolutionary therapy is obstacle, says CMO.
News Gilead swoops to buy Kite for $12billion Gilead has sealed a deal to acquire cell therapy leader Kite for just under $12 billion.
News Real world data essential for CAR-T therapy success Innovators will need to quantify value to bring costly drugs to market.
News Scottish firm gets EU funding for 'off the shelf' cancer cel... First patients could be treated in 2019.
News Kite files CAR-T therapy in EU, ahead of Novartis rival Kite eyes possible CAR-T launch next year.
Sales & Marketing Sponsored Health Trends 2025: Reimagining What's Possible Join the conversation, on Tuesday 28th January @ 10 am ET - 3 pm GMT - 4 pm CET, in our webinar sponsored by Syneos Health, entitled ‘Health Trends 2025: Reimagining What's Possibl
